studies

breast cancer - triple negative, pembrolizumab based treatment vs. Standard of Care (SoC), meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsKEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15] KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05] KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03] KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96] 0.87[0.80; 0.95]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 202060%3,027lowserious progression or deaths (PFS)detailed resultsKEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97] KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91] KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88] 1.00[0.75; 1.34]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020691%3,027lownot evaluable DCRdetailed resultsKEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94] 0.60[0.39; 0.94]KEYNOTE-119 (all population), 201910%622NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33] KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80] KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60] 1.01[0.47; 2.17]KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020694%3,027lownot evaluable AE (any grade)detailed resultsKEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87] 1.25[0.41; 3.87]KEYNOTE-355 (all population), 202010%843NAnot evaluable AE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76] 1.26[0.91; 1.76]KEYNOTE-355 (all population), 202010%843NAnot evaluable SAE (any grade)detailed resultsKEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48] 0.99[0.66; 1.48]KEYNOTE-119 (all population), 201910%601NAnot evaluable TRAE (any grade)detailed resultsKEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70] 1.35[0.68; 2.70]KEYNOTE-355 (all population), 202010%843NAnot evaluable TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43] KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44] 0.56[0.16; 1.99]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020296%1,444lownot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.00[0.41; 2.47]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63] 1.05[0.42; 2.63]KEYNOTE-119 (all population), 201910%601NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51] 0.84[0.22; 3.26]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01] KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71] 0.65[0.17; 2.54]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020276%1,444lownot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69] 1.26[0.28; 5.69]KEYNOTE-119 (all population), 201910%601NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.04[0.10; 10.27]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10] 0.23[0.05; 1.10]KEYNOTE-119 (all population), 201910%601NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72] KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82] 1.10[0.50; 2.40]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-119 (all population), 201910%601NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90] 0.98[0.07; 12.73]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.95[0.20; 19.31]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42] 1.91[0.57; 6.42]KEYNOTE-119 (all population), 201910%601NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48] 1.32[0.70; 2.49]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71] KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19] 0.46[0.07; 3.09]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020253%1,444lownot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] 5.72[0.29; 114.60]KEYNOTE-119 (all population), 201910%601NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69] 1.03[0.33; 3.14]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12] KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36] 0.11[0.00; 12.49]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020291%1,444lownot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08] 0.13[0.02; 1.08]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13] 0.16[0.01; 3.13]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78] 5.89[0.74; 47.15]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64] 3.82[0.61; 23.97]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444moderatenot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Urticaria TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22] 0.47[0.04; 5.22]KEYNOTE-119 (all population), 201910%601NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-09 00:37 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 324,142,305,306,98,96,269,60,143,270,140,240 - treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons